Prevalence of pathogenic or likely pathogenic germline mutations in patients with metastatic renal cell cancer.

Authors

Atul Batra

Atul Batra

Department of Medical Oncology, BRA-IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Atul Batra , Brusabhanu Nayak , Ranjit Kumar Sahoo , Seema Kaushal , Aparna Sharma , akash kumar , Amlesh Seth , Shamim Ahmed Shamim

Organizations

Department of Medical Oncology, BRA-IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India, All India Institute of Medical Sciences, New Delhi, India, Dr Brairch, All India Institute of Medical Sciences, New Delhi, India, Pathology, All India Institute of Medical Science, New Delhi, India, Dr. Brairch, All India Institute of Medical Sciences, New Delhi, India, All India Institute of Medical Sciences (AIIMS), New Delhi, India, Urology, All India Institute of Medical Sciences, New Delhi, India

Research Funding

No funding sources reported

Background: Data from the West suggests that 5-10% of patients with metastatic renal cell cancer (RCC) are known to harbor a pathogenic/likely pathogenic mutation in the RCC-associated genes. However, there are no data from the Indian subcontinent in this regard. Methods: This study was a prospective single-center cohort study conducted at a large tertiary care cancer center in northern India. Patients newly diagnosed with metastatic RCC were eligible to participate and, if willing, were offered pretest counseling and germline genetic testing. We performed whole exome sequencing on blood samples using next-generation sequencing on the Illumina platform. The frequency and spectrum of pathogenic/likely pathogenic (P/LP) variants were determined and classified using the ACMG guidelines, and clinical characteristics associated with mutation status were analyzed using a Fisher's exact test. Results: A total of 156 patients with metastatic RCC were enrolled in this study from October 2023 to February 2024. The median age at diagnosis was 44 years, and 67% were men. Histologically, 64% had clear cells, 12% had papillary, and 8% had unknown histology. In RCC-associated genes, 6 patients (3.8%) had P/Lp mutations, of which 4 had mutations in FH and 2 in VHL. Further P/LP variants in the non-RCC genes were detected in 12 additional patients (7.7%), of which 4 were in ATM, 2 in BRIP1, and one each in BRCA1, BARD1, PALB2, MUTYH, MSH6, and PMS2, respectively. The presence of germline P/LP mutation was associated with non-clear histology but not with age and sex. Patients with a P/LP mutation were more likely to have a family history of other cancers (most common, breast cancer) in first and second-degree relatives. Conclusions: 11.5% of patients with metastatic RCC were detected with germline P/LP variants, of which one-third had one of the RCC genes, and the rest had non-RCC gene mutations. Patients with mRCC should have access to germline genetic testing, and the gene panel for patients needs to be expanded to include genes previously classified as non-RCC genes.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Advanced Disease

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 110)

DOI

10.1200/JCO.2024.42.23_suppl.110

Abstract #

110

Poster Bd #

G10

Abstract Disclosures

Similar Abstracts

First Author: Nicole Casasanta

First Author: Mingwei Li

Abstract

2020 Genitourinary Cancers Symposium

Prevalence of pathogenic germline risk variants (PVs) in 1829 renal cell carcinoma (RCC) patients (pts).

First Author: Sarah Abou Alaiwi

First Author: June Evelyn Jeon